← Human Trials & Peer-Reviewed Studies
Effects of Dapagliflozin and Combination Therapy With Exenatide on Food-Cue Induced Brain Activation in Patients With Type 2 Diabetes
Plain-language guide to PMID 35134184 (2022): double-blind randomized controlled trial study of Exenatide.
Key Facts
- PMID
- 35134184
- Journal
- The Journal of clinical endocrinology and metabolism
- Year
- 2022
- Study type
- Randomized Controlled Trial
- Authors
- van Ruiten CC et al. (8 authors)
- DOI
- 10.1210/clinem/dgac043
What This Study Did, in Plain Language
What Was Tested
Researchers studied Exenatide in this randomized controlled trial publication.
The researchers investigated the separate and combined effects of dapagliflozin and exenatide on the CNS in participants with obesity and type 2 diabetes.
Why It Was Studied
Sodium-glucose cotransporter-2 inhibitors (SGLT2i) cause less weight loss than expected based on urinary calorie excretion.
Who Took Part
The age groups tagged for this paper are middle-aged adults.
Using functional MRI, the effects of treatments on CNS responses to viewing food pictures were assessed after 10 days and 16 weeks of treatment.
How the Study Was Run
The researchers set it up as a randomized, double-blind and placebo-controlled study.
Because people in this Exenatide study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.
As a double-blind Exenatide study, the assignments were hidden from both participants and investigators until the end.
Some participants received a placebo instead of Exenatide, giving a reference point.
A time span of 10 days appears in the methods.
This was a 16-week, double-blind, randomized, placebo-controlled trial.
What Was Measured
The subject headings attached to it are Benzhydryl Compounds, Blood Glucose, Brain, Cues, Diabetes Mellitus, Type 2, Exenatide and Glucosides.
Author keywords: GLP-1 receptor agonist, SGLT2 inhibitor, body weight, central nervous system, dapagliflozin and functional neuroimaging.
What This Means in Plain Language
The paper is a randomized, double-blind and placebo-controlled study of Exenatide over 10 days.
Its findings take up roughly 6 sentences of the abstract and are left out here on purpose; the source paper is the place to read them.
The publication is from 2022 (The Journal of clinical endocrinology and metabolism), a journal based in United States.
More context: the Exenatide compound page, all human trials.
Our Notes on the Compound
Exenatide: A 39-amino-acid GLP-1 receptor agonist first identified in Gila monster venom; sold as Byetta and Bydureon for type 2 diabetes.
Related Pages
Source: PubMed record. This explanation is written by PeptideWhiz from the public record. For research and education only. Not medical advice; no dosing information is given.